Molecular genetics of acute promyelocytic leukemia

Trends in Genetics

Volumn 15, Issue 5, 1999, Pages 179-184

  Lin, Richard J ^a   Egan, David A ^a   Evans, Ronald M ^a  

^a HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RETINOIC ACID RECEPTOR;

ACUTE MYELOBLASTIC LEUKEMIA; CELL DIFFERENTIATION; GENE MUTATION; HUMAN; LEUKEMOGENESIS; MOLECULAR GENETICS; NONHUMAN; PRIORITY JOURNAL; REVIEW; TRANSCRIPTION REGULATION; TRANSGENIC MOUSE;

ANIMALS; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MICE; MICE, TRANSGENIC; MOLECULAR BIOLOGY; MUTATION; RECEPTORS, RETINOIC ACID; TRANSLOCATION, GENETIC; TRETINOIN;

ANIMALIA; MUS MUSCULUS;

EID: 0032949304     PISSN: 01689525     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-9525(99)01710-2     Document Type: Review

References (69)

1. Warrell R.P. Jr.et al. Acute promyelocytic leukemia. New Engl. J. Med. 329:1993;177-189.
2. Huang M-E.et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood. 72:1988;567-572.
3. Warrell R.P. Jr.et al. Differentiation therapy for acute promyelocytic leukemia with tretinoin (all-trans retinoic acid). New Engl. J. Med. 324:1991;1385-1393.
4. Look A.T. Oncogenic transcription factors in the human acute leukemias. Science. 278:1997;1059-1064.
5. Zenke M.et al. v-erb A oncogene activation entails the loss of hormone-dependent regulator activity of c-erb A. Cell. 61:1990;1035-1049.
6. de Thé H.et al. The t(15;17) translocation of acute promyelocytic leukemia fuses the retinoic acid receptor α gene to a novel transcribed locus. Nature. 347:1990;558-561.
7. Borrow J.et al. Molecular analysis of acute promyelocytic leukemia breakpoint cluster region on chromosome 17. Science. 249:1990;1577-1580.
8. Grignani F.et al. Acute promyelocytic leukemia: from genetics to treatment. Blood. 83:1994;10-25.
9. Quignon F.et al. Retinoic acid and arsenic: towards oncogene-targeted treatments of acute promyelocytic leukemia. Biochim. Biophys. Acta. 1333:1997;M53-M61.
10. Kakizuka A.et al. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RARα with a novel putative transcription factor, PML. Cell. 66:1991;663-674.
11. de Thé H.et al. The PML-RARα fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell. 66:1991;675-684.
12. Chen Z.et al. Fusion between a novel krüppel-like zinc finger gene and the retinoic acid receptor-α locus due to a variant t(11;17) translocation associated with acute promyelocytic leukemia. EMBO J. 12:1993;1161-1167.
13. Redner R.L.et al. The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin-retinoic acid receptor fusion. Blood. 87:1996;882-896.
14. Wells R.A.et al. Fusion of retinoic acid receptor α to NuMA, the nuclear mitotic apparatus protein, by a variant translocation in acute promyelocytic leukemia. Nat. Genet. 17:1997;109-113.
15. Benedetti L.et al. Characterization of the retinoid binding properties of the major fusion products present in acute promyelocytic leukemia cells. Blood. 90:1997;1175-1185.
16. Dong S.et al. Amino-terminal protein-protein interaction motif (POZ domain) is responsible for activities of the promyelocytic leukemia zinc finger-retinoic acid receptor-α fusion protein. Proc. Natl. Acad. Sci. U. S. A. 93:1996;3624-3629.
17. Perez A.et al. PML/RAR homodimers: distinc DNA binding properties and heterodimeric interaction with RXR. EMBO J. 12:1993;3171-3182.
18. Rousselot P.et al. The PML-RARα gene product of the t(15;17) translocation inhibits retinoic acid-induced granulocytic differentiation and mediated transactivation in human myeloid cells. Oncogene. 9:1994;545-551.
19. Grignani F.et al. The acute promyelocytic leukemia-specific PML-RARα fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. Cell. 74:1993;423-431.
20. Ruthardt M.et al. Opposite effects of the acute promyelocytic leukemia PML-retinoic acid receptor α (RARα) and PLZF-RARα fusion proteins on retinoic acid signalling. Mol. Cell. Biol. 8:1997;4859-4869.
21. Licht J.D.et al. Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17). Blood. 85:1995;1083-1094.
22. Chen J.D., Evans R.M. A transcriptional co-repressor that interacts with nuclear hormone receptors. Nature. 377:1995;454-457.
23. Hörlein A.J.et al. Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. Nature. 377:1995;397-404.
24. Nagy L.et al. Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase. Cell. 89:1997;373-380.
25. Heinzel T.et al. A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression. Nature. 387:1997;43-48.
26. Alland L.et al. Role for N-CoR and histone deacetylase in Sin3-mediated transcriptional repression. Nature. 387:1997;49-55.
27. Hong S-H.et al. SMRT co-repressor interacts with PLZF and with the PML-retinoic acid receptor α (RARα) and PLZF/RARα oncoproteins associated with acute promyelocytic leukemia. Proc. Natl. Acad. Sci. U. S. A. 94:1997;9028-9033.
28. He L-Z.et al. Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL. Nat. Genet. 18:1998;126-135.
29. Lin R.J.et al. Role of the histone deacetylase complex in acute promyelocytic leukemia. Nature. 391:1998;811-814.
30. Grignani F.et al. Fusion proteins of the retinoic acid receptor-α recruit histone deacetylase in promyelocytic leukemia. Nature. 391:1998;815-818.
31. Guidez F.et al. Reduced retinoic acid-sensitivities of nuclear receptor co-repressor binding to PML- and PLZF-RARα underlie molecular pathogenesis and treatment of acute promyelocytic leukemia. Blood. 91:1998;2634-2642.
32. Yoh S.M.et al. Thyroid hormone resistance syndrome manifests as an aberrant interaction between mutant T3 receptors and transcriptional co-repressors. Mol. Endocrinol. 11:1997;470-480.
33. Wang J.et al. ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex. Proc. Natl. Acad. Sci. U. S. A. 95:1998;10860-10865.
34. Dyck J.A.et al. A novel macromolecular structure is a target of the promyelocyte-retinoic acid receptor oncoprotein. Cell. 76:1994;333-343.
35. Weis K.et al. Retinoic acid regulates aberrant nuclear localization of PML-RARα in acute promyelocytic leukemia cells. Cell. 76:1994;345-356.
36. Grimwade D.et al. Characterization of cryptic rearrangements and variant translocations in acute promyelocytic leukemia. Blood. 90:1997;4876-4885.
37. Doucas V., Evans R.M. The PML nuclear compartment and cancer. Biochim. Biophys. Acta. 1288:1996;M25-M29.
38. Mu Z-M.et al. PML, a growth suppressor disrupted in acute promyelocytic leukemia. Mol. Cell. Biol. 14:1994;6858-6867.
39. Wang Z.G.et al. Role of PML in cell growth and retinoic acid pathway. Science. 279:1998;1547-1551.
40. LaMorte V.J.et al. Localization of nascent RNA and CREB binding protein with the PML-containing nuclear body. Proc. Natl. Acad. Sci. U. S. A. 95:1998;4991-4996.
41. Doucas V.et al. Modulation of CBP function by the PML oncoprotein suggests a role for nuclear bodies in hormone signaling. Proc. Natl. Acad. Sci. U. S. A. 96:1999;2627-2632.
42. Vallian S.et al. Modulation of Fos-mediated AP-1 transcription by the promyelocytic leukemia protein. Oncogene. 16:1998;2843-2853.
43. Müller S.et al. Conjugation with the ubiquitin-related modifier SUMO-1 regulates the partitioning of PML within the nucleus. EMBO J. 17:1998;61-70.
44. Mahajan R.et al. A small ubiquitin-related polypeptide involved in targeting RanGAP1 to nuclear pore complex protein RanBP2. Cell. 88:1998;97-107.
45. Zheng P.et al. Proto-oncogene PML controls genes devoted to MHC class I antigen presentation. Nature. 396:1998;373-376.
46. Quignon F.et al. PML induces a novel caspase-independent death process. Nat. Genet. 20:1998;259-265.
47. Wang Z-G.et al. PML is essential for multiple apoptotic pathways. Nat. Genet. 20:1998;266-272.
48. He L-Z.et al. Acute leukemia with promyelocytic features in PML-RARα transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 94:1997;5302-5307.
49. Grisolano J.L.et al. Altered myeloid development and acute leukemia in transgenic mice expressing PML/RARα under control of cathepsin G regulatory sequence. Blood. 89:1997;376-387.
50. Brown D.et al. A PML/RARα transgene initiates murine acute promyelocytic leukemia. Proc. Natl. Acad. Sci. U. S. A. 94:1997;2551-2556.
51. Turhan A.G.et al. Highly purified primitive hematopoietic stem cells are PML-RARα negative and generate nonclonal progenitors in acute promyelocytic leukemia. Blood. 85:1995;2154-2162.
52. Shaknovich R.et al. The promyelocytic leukemia zinc finger protein affects myeloid cell growth, differentiation, and apoptosis. Mol. Cell. Biol. 18:1998;5533-5545.
53. Chomienne C.et al. All-trans retinoic acid modulates the retinoic acid receptor-alpha in promyelocytic cells. J. Clin. Invest. 88:1991;2150-2154.
54. Raelson J.V.et al. The PML/RARα oncoprotein is a direct target of retinoic acid in acute promyelocytic leukemia cells. Blood. 88:1996;2826-2832.
55. Benedetti L.et al. Retinoid-induced differentiation of acute promyelocytic leukemia involves PML-RARα-mediated increase of type II transglutaminase. Blood. 87:1996;1939-1950.
56. Ding W.et al. Leukemic cellular retinoic acid resistance and missense mutations in the PML-RARα fusion gene after relapse of acute promyelocytic leukemia from treatment with all-trans retinoic acid and intensive chemotherapy. Blood. 92:1998;1172-1183.
57. Imaizumi M.et al. Mutations in the E-domain of RAR portion of the PML/RAR chimeric gene may confer clinical resistance to all-trans retinoic acid in acute promyelocytic leukemia. Blood. 92:1998;374-382.
58. Shao W.et al. A retinoid-resistant acute promyelocytic leukemia subclone expresses a dominant negative PML-RARα mutation. Blood. 89:1997;4282-4289.
59. Nason-Burchenal K.et al. Targeting of PML/RARα is lethal to retinoic acid-resistant promyelocytic leukemia cells. Blood. 92:1998;1758-1767.
60. Nervi C.et al. Caspases mediate retinoic acid-induced degradation of the acute promyelocytic leukemia PML/RARα fusion protein. Blood. 92:1998;2244-2251.
61. Warrell R.P. Jr. Retinoid resistance in acute promyelocytic leukemia: new mechanisms, strategies, and implications. Blood. 79:1993;299-304.
62. Tobita T.et al. Treatment with a new synthetic retinoid, Am80, of acute promyelocytic leukemia relapsed from complete remission induced by ALL-trans retinoic acid. Blood. 90:1997;967-973.
63. Fujita H.et al. Vitamin K2 combined with all-trans retinoic acid induced complete remission of relapsing acute promyelocytic leukemia. Br. J. Hematol. 103:1998;584-585.
64. Warrell R.P. Jr.et al. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone decaetylase. J. Natl. Cancer Inst. 90:1998;1621-1625.
65. Soignet S.L.et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. New Engl. J. Med. 339:1998;1341-1348.
66. Gallagher R.E. Arsenic - new life for an old potion. New Engl. J. Med. 339:1998;1389-1391.
67. 3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RARα/PML proteins. Blood. 88:1996;1052-1061.
68. Zhu J.et al. Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia. Proc. Natl. Acad. Sci. U. S. A. 94:1997;3978-3983.
69. Wang Z.G.et al. Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARα independent manner. Blood. 92:1998;1497-1504.